{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:07:16Z","timestamp":1761948436104},"reference-count":107,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2019,3,29]]},"abstract":"<jats:sec><jats:title\/><jats:p>One of the greatest challenges of cancer therapeutics nowadays is to find selective targets successfully. Prostate apoptosis response-4 (Par-4) is a selective tumor suppressor protein with an interesting therapeutic potential due to its specificity on inducing apoptosis in cancer cells. Par-4 activity and levels can be downregulated in several tumors and cancer cell types, indicating poor prognosis and treatment resistance. Efforts to increase Par-4 expression levels have been studied, including its use as a therapeutic protein by transfection with adenoviral vectors or plasmids. However, gene therapy is very complex and still presents many hurdles to be overcome. We decided to review molecules and drugs with the capacity to upregulate Par-4 and, thereby, be an alternative to reach this druggable target. In addition, Par-4 localization and function are reviewed in some cancers, clarifying how it can be used as a therapeutic target.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666181126122440","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T11:52:34Z","timestamp":1543233154000},"page":"635-654","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Potential Therapeutic Agents Against Par-4 Target for Cancer Treatment: Where Are We Going?"],"prefix":"10.2174","volume":"20","author":[{"given":"Renata Virg\u00ednia Cavalcanti","family":"Santos","sequence":"first","affiliation":[{"name":"Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanessa Layssa Batista","family":"de Sena","sequence":"additional","affiliation":[{"name":"Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaviana Alves","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio Felix","family":"da Silva Filho","sequence":"additional","affiliation":[{"name":"Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Galdino","family":"da Rocha Pitta","sequence":"additional","affiliation":[{"name":"Laboratory of Planning and Synthesis of Drugs, NUPIT-SG, Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira Galdino","family":"da Rocha Pitta","sequence":"additional","affiliation":[{"name":"Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moacyr Barreto","family":"de Melo Rego","sequence":"additional","affiliation":[{"name":"Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelly Cristiny","family":"Pereira","sequence":"additional","affiliation":[{"name":"Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"457","volume":"5","author":"Sells S.","year":"1994","unstructured":"Sells S, Wood DP, Joshi-barve SS. Commonality of apoptosis of the gene programs in androgen-dependent prostate cells1 induced and by effectors.","journal-title":"Cell Growth Differ"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/MCB.17.7.3823","volume":"17","author":"Sells S.F.","year":"1997","unstructured":"Sells SF, Han SS, Muthukkumar S. Expression and function of the leucine zipper protein par-4 in apoptosis.","journal-title":"Mol Cell Biol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.4161\/cbt.7.12.6945","volume":"7","author":"Zhao Y.","year":"2008","unstructured":"Zhao Y, Rangnekar VM. Apoptosis and Tumor Resistance Conferred by Par-4.","journal-title":"Cancer Biol Ther"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/geno.1998.5494","volume":"53","author":"Johnstone R.W.","year":"1998","unstructured":"Johnstone RW, Tommerup N, Hansen C, Vissing H, Shi Y. Mapping of the Human PAWR (Par-4) Gene to Chromosome 12q21.","journal-title":"Genomics"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1128\/MCB.23.16.5516-5525.2003","volume":"23","author":"El-Guendy N.","year":"2003","unstructured":"El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells.","journal-title":"Mol Cell Biol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1002\/jcp.24098","volume":"227","author":"Hebbar N.","year":"2012","unstructured":"Hebbar N, Wang C, Rangnekar VM. Mechanisms of apoptosis by the tumor suppressor par-4.","journal-title":"J Cell Physiol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-05-4458","volume":"66","author":"Goswami A.","year":"2006","unstructured":"Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase\/akt1\/par-4 axis: a cancer-selective therapeutic target.","journal-title":"Cancer Res"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.onc.1202416","volume":"18","author":"Cook J.","year":"1999","unstructured":"Cook J, Krishnan S, Ananth S. Decreased expression of the pro-apoptotic protein par-4 in renal cell carcinoma.","journal-title":"Oncogene"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1158\/0008-5472.CAN-06-2687","volume":"67","author":"Moreno-Bueno G.","year":"2007","unstructured":"Moreno-Bueno G, Fernandez-Marcos PJ. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.","journal-title":"Cancer Res"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1054\/bjoc.2001.2158","volume":"85","author":"K\u00f6gel D.","year":"2001","unstructured":"K\u00f6gel D, Reimertz C, Mech P. Dlk\/ZIP kinase-induced apoptosis in human medulloblastoma cells: requirement of the mitochondrial apoptosis pathway.","journal-title":"Br J Cancer"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/ijo_00000651","volume":"37","author":"Nagai M.A.","year":"2010","unstructured":"Nagai MA, Gerhard R, Salaorni S. Down-regulation of the candidate tumor suppressos gene par-4 gene with poor prognosis in breast cancer.","journal-title":"Int J Oncol"},{"key":"ref=12","first-page":"1768","volume":"62","author":"Boehrer S.","year":"2002","unstructured":"Boehrer S, Chow KU, Beske F. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation.","journal-title":"Cancer Res"},{"key":"ref=13","volume":"2014","author":"Stewart BW","year":"2014","unstructured":"Stewart BW, Wild C. World cancer report.","journal-title":"World Cancer Rep"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.onc.1202344","volume":"18","author":"Qiu G.","year":"1999","unstructured":"Qiu G, Ahmed M, Sells SF. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4.","journal-title":"Oncogene"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bcp.2003.10.013","volume":"67","author":"Huang Y.T.","year":"2004","unstructured":"Huang YT, Chueh SC, Teng CM, Guh JH. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 Cells.","journal-title":"Biochem Pharmacol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/0008-5472.CAN-06-2430","volume":"67","author":"Srinivasan S.","year":"2007","unstructured":"Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.","journal-title":"Cancer Res"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/cddis.2015.403","volume":"7","author":"Das T.P.","year":"2016","unstructured":"Das TP, Suman S, Alatassi H, Ankem MK, Damodaran C. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer.","journal-title":"Cell Death Dis"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.6646","volume":"7","author":"Suman S.","year":"2016","unstructured":"Suman S, Das TP, Moselhy J, Pal D, Kolluru V. Oral administration of withaferin a inhibits carcinogenesis of prostate in TRAMP model.","journal-title":"Oncotarget"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neo.2017.04.005","volume":"19","author":"Moselhy J.","year":"2017","unstructured":"Moselhy J, Suman S, Alghamdi M. Withaferin a inhibits prostate carcinogenesis in a PTEN-Deficient mouse model of prostate cancer.","journal-title":"Neoplasia (United States)"},{"key":"ref=20","first-page":"109","volume":"63","author":"MacLean M.A.","year":"2011","unstructured":"MacLean MA, Scott BE, Deziel BA. North american cranberry (Vaccinium Macrocarpon) stimulates apoptotic pathways in DU145 human prostate cancer cells","journal-title":"Nutr Cancer"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/pr300968q","volume":"12","author":"Roumeliotis T.I.","year":"2013","unstructured":"Roumeliotis TI, Halabalaki M, Alexi X, Ankrett D. Pharmacoproteomic study of the natural product ebenfuran III in DU-145 prostate cancer cells: The quantitative and temporal interrogation of chemically induced cell death at the protein level.","journal-title":"J Proteome Res"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0135106","volume":"10","author":"Brasseur K.","year":"2015","unstructured":"Brasseur K, Auger P, Asselin E. Parasporin-2 from a new bacillus thuringiensis 4r2 strain induces caspases activation and apoptosis in human cancer cells.","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpls.2015.00822","volume":"6","author":"Sarkar S.","year":"2015","unstructured":"Sarkar S, Jain S, Rai V. Plant-derived SAC domain of par-4 (prostate apoptosis response 4) exhibits growth inhibitory effects in prostate cancer cells.","journal-title":"Front Plant Sci"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00299-011-1215-7","volume":"31","author":"Lico C.","year":"2012","unstructured":"Lico C, Santi L, Twym Lico C, Santi L, Twyman RM, Pezzotti M, Avesani L. The use of plants for the production of therapeutic human peptides.","journal-title":"Plant Cell Rep"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.biotechadv.2018.02.002","volume":"36","author":"Buyel J.F.","year":"2018","unstructured":"Buyel JF. Plants as sources of natural and recombinant anti-cancer agents.","journal-title":"Biotechnol Adv"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jcp.22461","volume":"226","author":"Rossi V.","year":"2011","unstructured":"Rossi V, Bellastella G, De Rosa C. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor\u03b1 and \u03b2.","journal-title":"J Cell Physiol"},{"key":"ref=27","volume":"7","author":"Rah B.","year":"2012","unstructured":"Rah B, Amin H, Yousuf K. A novel MMP-2 inhibitor 3-azidowithaferin A (3-AzidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4.","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/15548627.2015.1017182","volume":"11","author":"Rah B","year":"2015","unstructured":"Rah B. ur Rasool R, Nayak D, et al PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells.","journal-title":"Autophagy"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nchembio.1631","volume":"10","author":"Burikhanov R.","year":"2014","unstructured":"Burikhanov R, Sviripa VM, Hebbar N. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis.","journal-title":"Nat Chem Biol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1039\/C5OB01980J","volume":"14","author":"Sviripaa V.M.","year":"2016","unstructured":"Sviripaa VM, Burikhanovc R, Obieroe JM. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin vitaliy.","journal-title":"Org Biomol Chem"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.tetlet.2015.01.028","volume":"56","author":"Frasinyuka M.S.","year":"2015","unstructured":"Frasinyuka MS, Bondarenkob SP, Sviripac VM. Development of 6H-chromeno[3,4-c]pyrido[3\u2032,2\u2032:4,5]thieno[2,3- e]pyridazin-6-ones as Par-4 secretagogues.","journal-title":"Tetrahedron Lett"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.celrep.2016.12.051","volume":"18","author":"Burikhanov R.","year":"2017","unstructured":"Burikhanov R, Hebbar N, Noothi SK. Chloroquine-inducible Par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasis.","journal-title":"Cell Rep"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1091\/mbc.e02-03-0143","volume":"13","author":"Hattula K.","year":"2002","unstructured":"Hattula K, Furuhjelm J, Arffman A, Per\u00e4nen J. A rab8-specific gdp\/gtp exchange factor is involved in actin remodeling and polarized membrane transport.","journal-title":"Mol Biol Cell"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-4598-9-98","volume":"9","author":"Wang B-D.","year":"2010","unstructured":"Wang B-D, Kline CLB, Pastor DM. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-fu through mediation of an nf kappab and microrna network.","journal-title":"Mol Cancer"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0016-5085(00)70352-0","volume":"118","author":"Zhang Z.","year":"2000","unstructured":"Zhang Z, DuBois RN. Par-4, a proapoptotic gene, is regulated by nsaids in human colon carcinoma cells.","journal-title":"Gastroenterol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-8674(00)81664-5","volume":"99","author":"He T-C.","year":"1999","unstructured":"He T-C, Chan TA, Vogelstein B, Kinzler KW. PPAR\u03b4 is an apc-regulated target of nonsteroidal anti- inflammatory drugs.","journal-title":"Cell"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/cdd.2014.92","volume":"21","author":"Chen X.","year":"2014","unstructured":"Chen X, Sahasrabuddhe AA, Szankasi P. Fbxo45-mediated degradation of the tumor-suppressor par-4 regulates cancer cell survival.","journal-title":"Cell Death Differ"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/15384047.2016.1252880","volume":"18","author":"Nguyen J.Q.","year":"2017","unstructured":"Nguyen JQ, Irby RB. TRIM21 is a novel regulator of par-4 in colon and pancreatic cancer cells.","journal-title":"Cancer Biol Ther"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s10495-011-0648-3","volume":"16","author":"Kline C.L.B.","year":"2011","unstructured":"Kline CLB, Irby RB. The pro-apoptotic protein prostate apoptosis response protein-4 (par-4) can be activated in colon cancer cells by treatment with src inhibitor and 5-FU.","journal-title":"Apoptosis"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/MCB.25.3.1146-1161.2005","volume":"25","author":"Gurumurthy S.","year":"2005","unstructured":"Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of par-4 by protein kinase a is critical for apoptosis.","journal-title":"Mol Cell Biol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/1078-0432.CCR-10-2370","volume":"17","author":"Sharma A.K.","year":"2011","unstructured":"Sharma AK, Kline CL, Berg A, Amin S, Irby RB. The akt inhibitor isc-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model.","journal-title":"Clin Cancer Res"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-08-2214","volume":"15","author":"Sharma A.","year":"2009","unstructured":"Sharma A, Sharma AK, Madhunapantula SV. Targeting akt3 signaling in malignant melanoma using isoselenocyanates.","journal-title":"Clin Cancer Res"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.4161\/cbt.8.19.9592","volume":"8","author":"Kline C.L.","year":"2009","unstructured":"Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of par-4 plasmid nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-fu.","journal-title":"Cancer Biol Ther"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5123\/S2176-62232015000300006","volume":"6","author":"Barbosa SF","year":"2015","unstructured":"Barbosa SF. da C, Costa CA, et al. aspectos epidemiol\u00f3gicos dos casos de leucemia e linfomas em jovens e adultos atendidos em hospital de refer\u00eancia para c\u00e2ncer em bel\u00e9m, estado do par\u00e1, amaz\u00f4nia, Brasil.","journal-title":"Rev Pan-Amaz\u00f4nica Sa\u00fade"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2004.02.028","volume":"68","author":"Brieger A.","year":"2004","unstructured":"Brieger A, Boehrer S, Schaaf S. In Bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of par-4 increases sensitivity to imatinib (sti571) and histone deacetylase-inhibitors.","journal-title":"Biochem Pharmacol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.thj.6200089","volume":"2","author":"Boehrer S.","year":"2001","unstructured":"Boehrer S, Chow KU, Puccetti E. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia.","journal-title":"Hematol J"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1080\/1042819021000006510","volume":"43","author":"Boehrer S.","year":"2002","unstructured":"Boehrer S, Chow KU, Ruthardt M. Expression and function of prostate-apoptosis-response-gene-4 in lymphatic cells.","journal-title":"Leuk Lymphoma"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.leukres.2005.09.003","volume":"30","author":"Boehrer S.","year":"2006","unstructured":"Boehrer S, Nowak D, Puccetti E. Prostate-apoptosis-response-gene-4 increases sensitivity to trail-induced apoptosis.","journal-title":"Leuk Res"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428190009148847","volume":"36","author":"Faderl S.","year":"2000","unstructured":"Faderl S, Kantarjian HM, Piercea S, Albitar M, Estrov Z. Outcome of philadelphia chromosome-positive adult acute lymphoblastic.","journal-title":"Leuk Lymphoma"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.exphem.2004.04.004","volume":"32","author":"Kukoc-Zivojnov N.","year":"2004","unstructured":"Kukoc-Zivojnov N, Puccetti E, Chow KU. Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185bcr-abl in hematopoietic cells.","journal-title":"Exp Hematol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/10428190410001663617","volume":"45","author":"Boehrer S.","year":"2004","unstructured":"Boehrer S, Brieger A, Schaaf S. In the erythroleukemic cell line hel prostate-apoptosis-response-gene-4 (par-4) fails to down-regulate bcl-2 and to promote apoptosis.","journal-title":"Leuk Lymphoma"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2013.829574","volume":"55","author":"Zhang L.","year":"2014","unstructured":"Zhang L, Xu H-G, Lu C. A novel long non-coding rna t-all-r-lncr1 knockdown and par-4 cooperate to induce cellular apoptosis in t-cell acute lymphoblastic leukemia cells.","journal-title":"Leuk Lymphoma"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/sj.onc.1206271","volume":"22","author":"Roussigne M.","year":"2003","unstructured":"Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard J-P. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (par-4) to pml nuclear bodies.","journal-title":"Oncogene"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1038\/onc.2013.349","volume":"32","author":"Lu C.","year":"2013","unstructured":"Lu C, Li J-Y, Ge Z. Par-4\/THAP1 complex and notch3 competitively regulated pre-mrna splicing of ccar1 and affected inversely the survival of t-cell acute lymphoblastic leukemia cells.","journal-title":"Oncogene"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2403739","volume":"19","author":"Chow K.U.","year":"2005","unstructured":"Chow KU, Nowak D, Hofmann W, Schneider B, Hofmann W-K. Imatinib induces apoptosis in cll lymphocytes with high expression of par-4.","journal-title":"Leukemia"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2017-10-813931","volume":"131","author":"McKenna M.K.","year":"2018","unstructured":"McKenna MK, Noothi SK, Alhakeem SS. Novel role of prostate apoptosis response-4 tumor suppressor in b-cell chronic lymphocytic leukemia.","journal-title":"Blood"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ijc.23019","volume":"122","author":"Ahmed M.M.","year":"2008","unstructured":"Ahmed MM, Sheldon D, Fruitwala MA. Downregulation of par-4, a pro-apoptotic gene, in pancreatic tumors harboring k-ras mutation.","journal-title":"Int J Cancer"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2016.09.003","volume":"168","author":"Mann K.M.","year":"2016","unstructured":"Mann KM, Ying H, Juan J, Jenkins NA, Copeland G. KRAS-related proteins in pancreatic cancer.","journal-title":"Pharmacol Ther"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/14728222.2010.487066","volume":"14","author":"Azmi A.S.","year":"2010","unstructured":"Azmi AS, Philip PA, Zafar SF, Sarkar FH. PAR-4 as a possible new target for pancreatic cancer therapy.","journal-title":"Expert Opin Ther Targets"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s11095-008-9581-8","volume":"25","author":"Azmi A.S.","year":"2008","unstructured":"Azmi AS, Ahmad A, Banerjee S. Chemoprevention of pancreatic cancer\u202f: Characterization of par-4 and its modulation by 3, 3 \u2032diindolylmethane (DIM).","journal-title":"Pharm Res"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1158\/1535-7163.MCT-08-0438","volume":"7","author":"Azmi A.S.","year":"2008","unstructured":"Azmi AS, Wang Z, Burikhanov R. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis.","journal-title":"Mol Cancer Ther"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2012.10.036","volume":"144","author":"Azmi A.S.","year":"2013","unstructured":"Azmi AS, Aboukameel A, Bao B. Selective Inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.","journal-title":"Gastroenterol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.toxlet.2013.10.008","volume":"224","author":"Tan J.","year":"2014","unstructured":"Tan J, You Y, Xu T. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells pi3k\/akt pathway-dependent emt.","journal-title":"Toxicol Lett"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3322\/caac.21412","volume":"67","author":"DeSantis C.E.","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state.","journal-title":"CA Cancer J Clin"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gde.2003.12.005","volume":"14","author":"Zahir N.","year":"2004","unstructured":"Zahir N, Weaver VM. Death in the third dimension: apoptosis regulation and tissue architecture.","journal-title":"Curr Opin Genet Dev"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1091\/mbc.e07-10-1092","volume":"19","author":"Fung C.","year":"2008","unstructured":"Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of Autophagy during extracellular matrix detachment promotes cell survival.","journal-title":"Mol Biol Cell"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12307-010-0059-y","volume":"4","author":"de Bessa Garcia S.A.","year":"2011","unstructured":"de Bessa Garcia SA, Pereira MC, Nagai MA. Expression pattern of the pro-apoptotic gene par-4 during the morphogenesis of mcf-10a human mammary epithelial cells.","journal-title":"Cancer Microenviron"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1517\/14728222.2013.731047","volume":"17","author":"Irby R.B.","year":"2013","unstructured":"Irby RB, Kline CL. Par-4 as a potential target for cancer therapy.","journal-title":"Expert Opin Ther Targets"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2009.08.007","volume":"40","author":"Zapata-Benavides P.","year":"2009","unstructured":"Zapata-Benavides P, M\u00e9ndez-V\u00e1zquez JL, Gonz\u00e1lez-Rocha TR. Expression of prostate apoptosis response (par-4) is associated with progesterone receptor in breast cancer.","journal-title":"Arch Med Res"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ccr.2013.05.007","volume":"24","author":"Alvarez JV","year":"2013","unstructured":"Alvarez JV, Pan T. chi Ruth J, et al. Par-4 Downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy.","journal-title":"Cancer Cell"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.arcmed.2010.05.005","volume":"41","author":"M\u00e9ndez-L\u00f3pez L.F.","year":"2010","unstructured":"M\u00e9ndez-L\u00f3pez LF, Zapata-Benavides P, Zavala-Pompa A. Immunohistochemical analysis of prostate apoptosis response-4 (par-4) in mexican women with breast cancer: a preliminary study.","journal-title":"Arch Med Res"},{"key":"ref=72","first-page":"337","volume":"28","author":"Casolari D.A.","year":"2011","unstructured":"Casolari DA, Pereira MC, De Bessa Garcia SA, Nagai MA. Insulin-like Growth Factor-1 and 17B-Estradiol down-Regulate Prostate apoptosis response-4 expression in mcf-7 breast cancer cells.","journal-title":"Int J Mol Med"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3892\/ijo.2013.1983","volume":"43","author":"Pereira M.C.","year":"2013","unstructured":"Pereira MC, De Bessa-Garcia SA, Burikhanov R. Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in mcf-7 breast cancer cells.","journal-title":"Int J Oncol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"19995","DOI":"10.1074\/jbc.M205865200","volume":"278","author":"Cheema S.K.","year":"2003","unstructured":"Cheema SK, Mishra SK, Rangnekar VM. Par-4 Transcriptionally regulates bcl-2 through a wt1-binding site on the bcl-2 promoter.","journal-title":"J Biol Chem"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccr.2013.06.010","volume":"24","author":"Shrestha-Bhattarai T.","year":"2013","unstructured":"Shrestha-Bhattarai T, Hebbar N, Rangnekar VM. Par(-4) oxysm in breast cancer.","journal-title":"Cancer Cell"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/mc.22328","volume":"55","author":"Amin H.","year":"2016","unstructured":"Amin H, Nayak D, Ur Rasool R. Par-4 dependent modulation of cellular \u03b2-catenin by medicinal plant natural product derivative 3-azido withaferin A.","journal-title":"Mol Carcinog"},{"key":"ref=77","first-page":"1602","volume":"18","author":"Salis O.","year":"2014","unstructured":"Salis O, Bedir A, Ozdemir T, Okuyucu A, Alacam H. The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line.","journal-title":"Eur J Pharm Sci"},{"key":"ref=78","first-page":"384","author":"Sarkar A.","year":"2016","unstructured":"Sarkar A, Chiocca EA.","journal-title":"Glioblastoma and malignant astrocytoma"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1038\/nrdp.2015.17","volume":"16","author":"Weller M.","year":"2015","unstructured":"Weller M, Wick W, Aldape K. Glioma.","journal-title":"Nat Rev Dis Prim"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"Louis D.N.","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G. The 2016 world health organization classification of tumors of the central nervous system: a summary.","journal-title":"Acta Neuropathol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Wang Q.","year":"2017","unstructured":"Wang Q, Hu B, Hu X. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment.","journal-title":"Cancer Cell"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"Yan H.","year":"2009","unstructured":"Yan H, Jones S, Riggins GJ. IDH1 and IDH2 mutations in gliomas.","journal-title":"New English J Med"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","volume":"174","author":"Watanabe T.","year":"2009","unstructured":"Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.","journal-title":"Am J Pathol"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","volume":"102","author":"Reitman Z.J.","year":"2010","unstructured":"Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.","journal-title":"J Natl Cancer Inst"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00401-014-1334-7","volume":"128","author":"Liu Y.","year":"2014","unstructured":"Liu Y, Glibert MR, Kyprianou N, Rangnekar VM, Horbinski C. The Tumor suppressor prostate apoptosis response-4 (par-4) is regulated by mutant idh1 and kills glioma stem cells.","journal-title":"Acta Neuropathol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"11268","DOI":"10.18632\/oncotarget.24109","volume":"9","author":"Zou J.","year":"2018","unstructured":"Zou J, Zhu L, Jiang X. Curcumin Increases Breast Cancer Cell Sensitivity to Cisplatin by Decreasing FEN1 Expression.","journal-title":"Oncotarget"},{"key":"ref=87","first-page":"9384","volume":"20","author":"Kanai M.","year":"2014","unstructured":"Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer.","journal-title":"World J Gastroenterol"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2014.01.012","volume":"346","author":"Li Y.","year":"2014","unstructured":"Li Y, Zhang T. Targeting cancer stem cells by curcumin and clinical applications.","journal-title":"Cancer Lett"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.fob.2014.08.005","volume":"4","author":"Thayyullathil F.","year":"2014","unstructured":"Thayyullathil F, Rahman A, Pallichankandy S, Patel M, Galadari S. ROS-dependent prostate apoptosis response-4 (par-4) up-regulation and ceramide generation are the prime signaling events associated with curcumin-induced autophagic cell death in human malignant glioma.","journal-title":"FEBS Open Bio"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"e88505","DOI":"10.1371\/journal.pone.0088505","volume":"9","author":"Jagtap J.C.","year":"2014","unstructured":"Jagtap JC, Dawood P, Shah RD. Expression and regulation of prostate apoptosis response-4 (par-4) in human glioma stem cells in drug-induced apoptosis.","journal-title":"PLoS One"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.fob.2014.11.005","volume":"5","author":"Jagtap J.C.","year":"2015","unstructured":"Jagtap JC, Parveen D, Shah RD. Secretory prostate apoptosis response (par)-4 sensitizes multicellular spheroids (mcs) of glioblastoma multiforme cells to tamoxifen-induced cell death.","journal-title":"FEBS Open Bio"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2018.04.009","volume":"426","author":"Subburayan K.","year":"2018","unstructured":"Subburayan K, Thayyullathil F, Pallichankandy S, Rahman A, Galadari S. Par-4-Dependent p53 up-regulation plays a critical role in thymoquinone-induced cellular senescence in human malignant glioma cells.","journal-title":"Cancer Lett"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"Fern\u00e1ndez-Pello S.","year":"2017","unstructured":"Fern\u00e1ndez-Pello S, Hofmann F, Tahbaz R. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma.","journal-title":"Eur Urol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jcb.22504","volume":"109","author":"Lee T-J.","year":"2010","unstructured":"Lee T-J, Jang J-H, Noh H-J. Overexpression of par-4 sensitizes trail-induced apoptosis inactivation of nf-kappab and akt signaling pathways in renal cancer cells.","journal-title":"J Cell Biochem"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S1470-2045(13)70591-6","volume":"15","author":"Murali R.","year":"2014","unstructured":"Murali R, Soslow RA, Weigelt B. Classification of Endometrial carcinoma: more than two types.","journal-title":"Lancet Oncol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/humupd\/dmm009","volume":"13","author":"Groothuis P.G.","year":"2007","unstructured":"Groothuis PG, Dassen HH, Romano A, Punyadeera C. Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human.","journal-title":"Hum Reprod Update"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"36971","DOI":"10.18632\/oncotarget.9235","volume":"7","author":"Brasseur K.","year":"2016","unstructured":"Brasseur K, Fabi F, Adam P. Post-translational regulation of the cleaved fragment of par-4 in ovarian and endometrial cancer cells.","journal-title":"Oncotarget"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2680","volume":"221","author":"Saegusa M.","year":"2010","unstructured":"Saegusa M, Hashimura M, Kuwata T, Okayasu I. Transcriptional regulation of pro-apoptotic par-4 by nf-kb\/p65 and its function in controlling cell kinetics during early events in endometrial tumourigenesis.","journal-title":"J Pathol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.18632\/oncotarget.14021","volume":"8","author":"Brasseur K.","year":"2017","unstructured":"Brasseur K, Gevry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers.","journal-title":"Oncotarget"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/MCB.06321-11","volume":"32","author":"Chaudhry P.","year":"2012","unstructured":"Chaudhry P, Singh M, Parent S, Asselin E. Prostate apoptosis response 4 (par-4), a novel substrate of caspase-3 during apoptosis activation.","journal-title":"Mol Cell Biol"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/mc.22828","volume":"57","author":"Katoch A.","year":"2018","unstructured":"Katoch A, Suklabaidya S, Chakraborty S, Nayak D. Dual role of par-4 in abrogation of emt and switching on mesenchymal to epithelial transition (met) in metastatic pancreatic cancer cells.","journal-title":"Mol Carcinog"},{"key":"ref=102","first-page":"1037","volume":"16","author":"Gashaw I.","year":"2011","unstructured":"Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target?\u202fdrug discov.","journal-title":"Today"},{"key":"ref=103","first-page":"7255","volume":"61","author":"Apoptosis C.","year":"2001","unstructured":"Apoptosis C, Regression T, Chakraborty M. Par-4 drives trafficking and activation of fas and fasl to induce prostate cancer.","journal-title":"Cancer Res"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.1158\/0008-5472.CAN-07-2124","volume":"67","author":"Zhao Y.","year":"2007","unstructured":"Zhao Y, Burikhanov R, Qiu S. Cancer resistance in transgenic mice expressing the sac module of par-4.","journal-title":"Cancer Res"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4161\/cbt.12.2.15734","volume":"12","author":"Zhao Y.","year":"2011","unstructured":"Zhao Y, Burikhanov R, Brandon J. Systemic par-4 inhibits non-autochthonous tumor growth.","journal-title":"Cancer Biol Ther"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1615\/CritRevOncog.2016016084","volume":"21","author":"Lara-guerra H.","year":"2016","unstructured":"Lara-guerra H, Roth J. Gene therapy for lung cancer.","journal-title":"Crit Rev Onocogenes"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.bmb.a072939","volume":"51","author":"Weatherall D.J.","year":"1995","unstructured":"Weatherall DJ. Scope and limitations of gene therapy.","journal-title":"Br Med Bull"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/167737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T19:24:12Z","timestamp":1720812252000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/167737\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666181126122440","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}